Immune and inflammatory cells in thyroid cancer microenvironment
SM Ferrari, P Fallahi, MR Galdiero, I Ruffilli… - International journal of …, 2019 - mdpi.com
A hallmark of cancer is the ability of tumor cells to avoid immune destruction. Activated
immune cells in tumor microenvironment (TME) secrete proinflammatory cytokines and …
immune cells in tumor microenvironment (TME) secrete proinflammatory cytokines and …
Thyroid autoimmune disorders and cancer
SM Ferrari, P Fallahi, G Elia, F Ragusa, I Ruffilli… - Seminars in cancer …, 2020 - Elsevier
In the last decades, many studies conducted in vitro, and in vivo, have shown that thyroid
autoimmunity and thyroid cancer (TC)(mainly papillary TC) can be concomitant, even if the …
autoimmunity and thyroid cancer (TC)(mainly papillary TC) can be concomitant, even if the …
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
JM Mehnert, A Varga, MS Brose, RR Aggarwal, CC Lin… - BMC cancer, 2019 - Springer
Background Treatment options for advanced thyroid cancer refractory to standard therapies
are limited. The safety and efficacy of pembrolizumab were evaluated in patients with …
are limited. The safety and efficacy of pembrolizumab were evaluated in patients with …
Thyroid disorders induced by checkpoint inhibitors
SM Ferrari, P Fallahi, F Galetta, E Citi… - Reviews in Endocrine …, 2018 - Springer
Immune checkpoint inhibitors are drugs that inhibit the “checkpoint molecules”. Different
types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 …
types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 …
Multikinase inhibitors in thyroid cancer: timing of targeted therapy
In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer
with multikinase inhibitors, much has changed in the landscape of this heterogeneous …
with multikinase inhibitors, much has changed in the landscape of this heterogeneous …
New insight in endocrine-related adverse events associated to immune checkpoint blockade
G Elia, SM Ferrari, MR Galdiero, F Ragusa… - Best Practice & …, 2020 - Elsevier
Anticancer immunotherapy, in the form of immune checkpoint inhibition, is a paradigm shift
that has transformed the care of patients with different types of solid and hematologic …
that has transformed the care of patients with different types of solid and hematologic …
The immune landscape of thyroid cancer in the context of immune checkpoint inhibition
G Varricchi, S Loffredo, G Marone, L Modestino… - International Journal of …, 2019 - mdpi.com
Immune cells play critical roles in tumor prevention as well as initiation and progression.
However, immune-resistant cancer cells can evade the immune system and proceed to form …
However, immune-resistant cancer cells can evade the immune system and proceed to form …
Autoimmune endocrine dysfunctions associated with cancer immunotherapies
Immune checkpoint inhibitors block the checkpoint molecules. Different types of cancer
immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies …
immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies …
Role of chemokines in thyroid cancer microenvironment: is CXCL8 the main player?
M Rotondi, F Coperchini, F Latrofa… - Frontiers in …, 2018 - frontiersin.org
Tumor-related inflammation does influence the biological behavior of neoplastic cells and
ultimately the patient's outcome. With specific regard to thyroid cancer, the issue of tumor …
ultimately the patient's outcome. With specific regard to thyroid cancer, the issue of tumor …
State of the art in the current management and future directions of targeted therapy for differentiated thyroid cancer
H Silaghi, V Lozovanu, CE Georgescu, C Pop… - International Journal of …, 2022 - mdpi.com
Two-thirds of differentiated thyroid cancer (DTC) patients with distant metastases would be
classified as radioactive iodine-refractory (RAIR-DTC), evolving into a poor outcome. Recent …
classified as radioactive iodine-refractory (RAIR-DTC), evolving into a poor outcome. Recent …